← Eichor
Condition: Refractory Recurrent Peripheral T Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Recurrent Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell L
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07164560A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Haihe Biopharma Co., Ltd. · NCT06909877Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 · 2 location(s) · Mayo Clinic · NCT06508463Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase 2 · 1 location(s) · National Cancer Centre, Singapore · NCT06160843Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Rong Tao · NCT07502768A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06966154An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal A
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Soochow University · NCT075985783'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT05934513Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 · 15 location(s) · Prescient Therapeutics, Ltd. · NCT06854653Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell
Phase 1/Phase 2 · 4 location(s) · City of Hope Medical Center · NCT03011814Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT05079282Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05313243Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05996185A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1 · 5 location(s) · Treeline Biosciences, Inc. · NCT06733441A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma W
Phase 3 · 44 location(s) · SecuraBio · NCT06522737SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06122389Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06810778A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NA · 1 location(s) · Shenzhen University General Hospital · NCT05620680Amping up With PemJAK
Phase 2 · 1 location(s) · Seda S. Tolu · NCT07283822
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.